NMRA (Neumora Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on NMRA (Neumora Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

NMRA

Neumora Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 6, 2025
Neumora Therapeutics to Participate in Upcoming Conferences in November
Nov 3, 2025
Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity
Oct 31, 2025
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating
Oct 31, 2025
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Oct 27, 2025
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Oct 27, 2025
Neumora Therapeutics to Host Virtual R&D Day on October 27
Oct 1, 2025
Neumora Therapeutics to Participate in Upcoming Conferences in September
Sep 2, 2025
Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861
Aug 20, 2025
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 6, 2025
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating
Jul 29, 2025
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Jul 23, 2025
Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating
Jul 20, 2025

Reviews